https://investingnews.com/daily/life-science-investing/genetics-investing/jama-oncology-publication-demonstrates-endopredict-significantly-outperforms-oncotype-dx/
JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX | INN
Jan 5, 2026 - Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage...
jama oncologypublicationdemonstratesendopredictsignificantly
https://www.prnewswire.com/news-releases/myprostatescore-2-0-clinically-validated-in-new-jama-oncology-study-302121227.html
MyProstateScore 2.0 Clinically Validated in New JAMA Oncology Study
/PRNewswire/ -- Lynx Dx, a leader in innovative diagnostic solutions, hailed new peer-reviewed research published today in the Journal of the American...
2 0jama oncologyvalidatednewstudy
https://www.ama-assn.org/about/publications-newsletters/new-journal-jama-oncology-debut-2015
New journal JAMA Oncology to debut in 2015 | American Medical Association
The JAMA Network will launch a new journal JAMA Oncology featuring cancer-related research. It will be the 11th journal in the network, which includes the...
new journaljama oncology
https://www.wolterskluwer.com/en-in/solutions/ovid/jama-oncology-13521
Ovid - JAMA Oncology | Wolters Kluwer
Committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients...
jama oncologyovidwolterskluwer
https://www.wolterskluwer.com/en-ph/solutions/ovid/jama-oncology-13521
Ovid - JAMA Oncology | Wolters Kluwer
Committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients...
jama oncologyovidwolterskluwer